Jeff Yass’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $32.3M | Buy |
395,662
+187,724
| +90% | +$13.6M | ﹤0.01% | 1935 |
|
|
2026
Q1 | $14.2M | Buy |
207,938
+189,257
| +1,013% | +$13.4M | ﹤0.01% | 2633 |
|
|
2025
Q4 | $1.42M | Sell |
18,681
-20,669
| -53% | -$1.5M | ﹤0.01% | 6387 |
|
|
2025
Q3 | $2.41M | Sell |
39,350
-392,380
| -91% | -$20.4M | ﹤0.01% | 5393 |
|
|
2025
Q2 | $21.1M | Buy |
431,730
+325,663
| +307% | +$15.5M | ﹤0.01% | 1953 |
|
|
2025
Q1 | $5.41M | Buy |
106,067
+4,398
| +4% | +$219K | ﹤0.01% | 3516 |
|
|
2024
Q4 | $4.59M | Buy |
101,669
+79,527
| +359% | +$3.4M | ﹤0.01% | 3732 |
|
|
2024
Q3 | $821K | Buy |
22,142
+5,957
| +37% | +$199K | ﹤0.01% | 7287 |
|
|
2024
Q2 | $495K | Sell |
16,185
-37,249
| -70% | -$1.21M | ﹤0.01% | 8299 |
|
|
2024
Q1 | $1.55M | Buy |
53,434
+28,968
| +118% | +$811K | ﹤0.01% | 5921 |
|
|
2023
Q4 | $674K | Sell |
24,466
-72,996
| -75% | -$1.67M | ﹤0.01% | 7934 |
|
|
2023
Q3 | $2.18M | Sell |
97,462
-17,344
| -15% | -$645K | ﹤0.01% | 4955 |
|
|
2023
Q2 | $4.67M | Sell |
114,806
-7,543
| -6% | -$369K | ﹤0.01% | 3654 |
|
|
2023
Q1 | $5.93M | Buy |
122,349
+79,274
| +184% | +$3.62M | ﹤0.01% | 3195 |
|
|
2022
Q4 | $1.64M | Sell |
43,075
-27,931
| -39% | -$1.16M | ﹤0.01% | 5084 |
|
|
2022
Q3 | $3.56M | Buy |
71,006
+17,809
| +33% | +$873K | ﹤0.01% | 3743 |
|
|
2022
Q2 | $2.13M | Buy |
53,197
+12,447
| +31% | +$436K | ﹤0.01% | 4785 |
|
|
2022
Q1 | $1.52M | Sell |
40,750
-16,075
| -28% | -$619K | ﹤0.01% | 6102 |
|
|
2021
Q4 | $2.26M | Buy |
56,825
+3,036
| +6% | +$116K | ﹤0.01% | 5224 |
|
|
2021
Q3 | $2M | Buy |
53,789
+17,141
| +47% | +$704K | ﹤0.01% | 5832 |
|
|
2021
Q2 | $1.55M | Sell |
36,648
-5,515
| -13% | -$236K | ﹤0.01% | 6548 |
|
|
2021
Q1 | $2M | Buy |
42,163
+28,634
| +212% | +$1.7M | ﹤0.01% | 5926 |
|
|
2020
Q4 | $826K | Sell |
13,529
-4,237
| -24% | -$250K | ﹤0.01% | 7161 |
|
|
2020
Q3 | $830K | Buy |
17,766
+142
| +0.8% | +$6.99K | ﹤0.01% | 6571 |
|
|
2020
Q2 | $894K | Sell |
17,624
-48,771
| -73% | -$2.4M | ﹤0.01% | 6171 |
|
|
2020
Q1 | $2.96M | Buy |
+66,395
| New | +$3.34M | ﹤0.01% | 3304 |
|
|
2019
Q4 | – | Sell |
-37,731
| Closed | -$1.6M | – | 10435 |
|
|
2019
Q3 | $1.28M | Sell |
37,731
-10,325
| -21% | -$449K | ﹤0.01% | 5168 |
|
|
2019
Q2 | $2.16M | Buy |
+48,056
| New | +$1.9M | ﹤0.01% | 4025 |
|
|
2018
Q3 | – | Sell |
-9,010
| Closed | -$373K | – | 10037 |
|
|
2018
Q2 | $304K | Buy |
+9,010
| New | +$281K | ﹤0.01% | 7819 |
|
|
2018
Q1 | – | Sell |
-265,051
| Closed | -$6.72M | – | 10003 |
|
|
2017
Q4 | $4.42M | Buy |
265,051
+127,081
| +92% | +$2.15M | ﹤0.01% | 2681 |
|
|
2017
Q3 | $2.76M | Buy |
137,970
+75,240
| +120% | +$1.47M | ﹤0.01% | 3359 |
|
|
2017
Q2 | $1.15M | Buy |
+62,730
| New | +$845K | ﹤0.01% | 4971 |
|
|
2017
Q1 | – | Sell |
-131,449
| Closed | -$1.59M | – | 9741 |
|
|
2016
Q4 | $1.43M | Buy |
+131,449
| New | +$1.38M | ﹤0.01% | 4770 |
|
|
2016
Q3 | – | Sell |
-104,188
| Closed | -$847K | – | 8900 |
|
|
2016
Q2 | $731K | Buy |
104,188
+54,667
| +110% | +$401K | ﹤0.01% | 5456 |
|
|
2016
Q1 | $319K | Buy |
+49,521
| New | +$859K | ﹤0.01% | 7162 |
|
|
2015
Q4 | – | Sell |
-133,540
| Closed | -$3.93M | – | 9854 |
|
|
2015
Q3 | $3.57M | Buy |
133,540
+95,324
| +249% | +$4.08M | ﹤0.01% | 3197 |
|
|
2015
Q2 | $1.84M | Sell |
38,216
-73,154
| -66% | -$4.27M | ﹤0.01% | 4903 |
|
|
2015
Q1 | $6.78M | Buy |
111,370
+95,589
| +606% | +$5.83M | ﹤0.01% | 2319 |
|
|
2014
Q4 | $817K | Buy |
+15,781
| New | +$695K | ﹤0.01% | 6259 |
|
|
2014
Q3 | – | Sell |
-10,666
| Closed | -$279K | – | 9835 |
|
|
2014
Q2 | $279K | Buy |
10,666
+909
| +9% | +$19.5K | ﹤0.01% | 8502 |
|
|
2014
Q1 | $255K | Buy |
+9,757
| New | +$262K | ﹤0.01% | 7850 |
|
Other funds holding PTCT
RI
JT
Jeff Yass's PTCT Position: Q2 2026 in Review
Jeff Yass increased its PTC Therapeutics (PTCT) stake by 90% in Q2 2026, buying an estimated $13.6M and bringing the position to 395,662 shares worth $32.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1935.
Jeff Yass first reported a position in PTCT in Q1 2014 and has held it in 41 quarters since. 381 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- Jeff Yass held 395,662 shares of PTC Therapeutics worth $32.3M as of Q2 2026.
- Jeff Yass bought 187,724 PTC Therapeutics shares in Q2 2026, an estimated $13.6M.
- PTC Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #1935 holding.
- Jeff Yass first reported a position in PTC Therapeutics in Q1 2014 and has held it in 41 quarters since.
- 381 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.